A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.

Phase 2

Amgen

Alendronate
Denosumab